Buone news for the treatment of metastatic breast cancer and for the negative triple (MTNBC). Today the news is that a conjugated drug-anti-anti (ADC) has obtained a new indication AIFA For the care of the Metastatic Mammary Carcinoma HR+/Her2- and, at the same time, the use of the second line for the treatment of Another form of metastatic breast cancer, the triple negative one.
Breast cancer, the new drug that can take care of it
The announcement was made to the press today 12 March 2025 in Milan. The new cure is called Sacituzumab Govitecana conjugated drug-anti-anti (ADC).
Every year in Italy there are about 13,000 new cases of metastatic cancer, About 40,000 women in Italy currently coexist with breast cancer that has developed metastases. HR+/Her2 breast cancer (HR-positive, Her2-NEGATIVE) is about 70% of breast cancer diagnoses. In the metastatic form it has a five -year survival rate of 34%. In Italy every year there are about 6-8,000 new cases of this type.
New breast cancer drugs are innovative
The conjugated drugs-antibodies have revolutionized tumors in recent years. These are drugs capable of recognizing cancer cells Taking advantage of the receptors on their surface and then attack them and destroy them from the inside, releasing a chemotherapy substance selectively. Now the drug can also be anticipated to the second line of cure of the so -called metastatic breast cancer ‘triple negative’Usually considered difficult to treat. This will allow treatment in an early phase of the diseasewhen the response possibilities are greater.
What is Her2-negative breast cancer
On Over 55 thousand new breast cancer diagnoses recorded in Italy every yearabout 80-85% is classified as Her2-negative. This type excluded the possibility of using Trasuzumab Deruxtecan. But now the research has discovered that many of the Her2-negative tumors express still low levels of HER2 receptor (hence the concept of Her2-Low). And thanks to a team of international experts led by Paolo Tarantino and coordinated by Professor Giuseppe Curigliano, co -director of the program New IEO drugstoday the Her2 Low classification is internationally recognized. From this new classification, in recent years they have started experiments aimed at trying to exploit the antibodies married in those women who were not considered suitable before.
The appeal to the prevention of Dr. Paola Martinoni of the Libellular Foundation Together
Dr. Paola Martinoni, founder of the Libellular Foundation Together (Courtesy Libellular Foundation Together)
The new drug was welcomed with great emotion by oncologists and above all by doctors who founded associations that deal with oncological patients. As Libellular Foundation Togetherwhich since 2015 has followed hundreds of women (but also men, given that breast cancer concerns everyone). «In addition to what has been said about the great innovation of this drug, I would like focus attention on the importance of prevention. It is not just a right (see Article 32 of the Constitution), But I firmly believe it is also a civic duty In addition to themselves and the people who love us », explains the Doctor Paola Martinoni, Surgea surgery, expert in first and second level diagnostics for the prevention of breast cancer. Dr. Martinoni is also the founder of Libellular Foundation Together And for years he has been dedicated to the follow-up of oncological patients and their physical and psychological support.
How much does chemotherapy cost?
An important reflection also on the economic aspect of oncological care. «Undergo the annual or regular checks indicated by the specialist, that is “Prevention”allows you not to get to a late diagnosis, when it is often objectively late to guarantee the healing or salvation of patients.
And it is also a way In order not to have to resort to Chiemotherapy, which in addition to being a very physically and mentally demanding care for patients and their family also has a very high cost for the state. A cycle of chemo costs at least 50 thousand euros. If we multiply this figure for all patients who have to do it we understand how much the social cost of advanced state diseases that have been neglected and discovered too late. Well, this money could be invested for scientific research and save many other lives, if the prevention was done regularly “, concludes Dr. Martinoni.
I woman © RESERVED REPRODUCTION